Current Promotions

No active promotions at the moment. Check back later for special offers!

No video available

Get in Touch

Call Now Visit Website

About

Alzinova AB is a Swedish clinical-stage biopharma company developing treatments for Alzheimer's disease by specifically targeting neurotoxic amyloid beta oligomers. The lead candidate, ALZ-101, is a therapeutic vaccine for the treatment of Alzheimer's. Alzinova's proprietary AβCC peptide™ technology enables the development of disease-modifying therapies that has unique ability and precision to target the toxic amyloid-beta oligomers involved in the onset and progression of the disease. Alzheimer's is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further.

Keywords

No keywords available

Amenities

No amenities listed yet

Upcoming Events

No upcoming events scheduled

Frequently Asked Questions

No FAQs available for this business.

Reviews

No reviews yet. Be the first to review!

Social Links

No social media links available

Photo Gallery

No photos available

Business Info

10
2011
$128.0K

Business Hours

Business hours not available

Own This Business?

Unclaimed

Take control of your business page to update information, respond to reviews, and more.

Claim This Business